| Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome CM Legendre, C Licht, P Muus, LA Greenbaum, S Babu, C Bedrosian, ... New England Journal of Medicine 368 (23), 2169-2181, 2013 | 1636 | 2013 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1572 | 2019 |
| Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies C Licht, LA Greenbaum, P Muus, S Babu, CL Bedrosian, DJ Cohen, ... Kidney international 87 (5), 1061-1073, 2015 | 454 | 2015 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 448 | 2021 |
| Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of Clinical Oncology 40 (28), 3246-3256, 2022 | 307 | 2022 |
| Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation—positive advanced non … DR Spigel, C Reynolds, D Waterhouse, EB Garon, J Chandler, S Babu, ... Journal of Thoracic Oncology 13 (5), 682-688, 2018 | 204 | 2018 |
| Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer, including patients … DR Spigel, M McCleod, RM Jotte, L Einhorn, L Horn, DM Waterhouse, ... Journal of Thoracic Oncology 14 (9), 1628-1639, 2019 | 174 | 2019 |
| The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment E Rondeau, M Scully, G Ariceta, T Barbour, S Cataland, N Heyne, ... Kidney international 97 (6), 1287-1296, 2020 | 155 | 2020 |
| Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non–small-cell lung cancer: CheckMate 153 DM Waterhouse, EB Garon, J Chandler, M McCleod, M Hussein, R Jotte, ... Journal of Clinical Oncology 38 (33), 3863, 2020 | 152 | 2020 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 131 | 2023 |
| Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma NH Fowler, F Samaniego, W Jurczak, N Ghosh, E Derenzini, JA Reeves, ... Journal of Clinical Oncology 39 (15), 1609, 2021 | 126 | 2021 |
| Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma DJ Olson, Z Eroglu, B Brockstein, AS Poklepovic, M Bajaj, S Babu, ... Journal of Clinical Oncology 39 (24), 2647, 2021 | 125 | 2021 |
| Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) DR Spigel, M McLeod, MA Hussein, DM Waterhouse, L Einhorn, L Horn, ... Annals of Oncology 28, v461, 2017 | 120 | 2017 |
| Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes G Garcia‐Manero, G Montalban‐Bravo, JG Berdeja, Y Abaza, E Jabbour, ... Cancer 123 (6), 994-1002, 2017 | 107 | 2017 |
| Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease R Sukhija, WS Aronow, K Yalamanchili, SJ Peterson, WH Frishman, ... Cardiology 103 (3), 158-160, 2005 | 100 | 2005 |
| Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer R Kollipara, B Schneider, M Radovich, S Babu, PJ Kiel The oncologist 22 (10), 1149-1151, 2017 | 76 | 2017 |
| Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine DA Pollyea, KW Pratz, AH Wei, V Pullarkat, BA Jonas, C Recher, S Babu, ... Clinical Cancer Research 28 (24), 5272-5279, 2022 | 71 | 2022 |
| Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma AJ Olszewski, A Avigdor, S Babu, I Levi, U Abadi, H Holmes, M McKinney, ... Blood 136, 43-45, 2020 | 61 | 2020 |
| ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine H Döhner, KW Pratz, CD DiNardo, BA Jonas, VA Pullarkat, MJ Thirman, ... Blood 140 (Supplement 1), 1441-1444, 2022 | 46 | 2022 |
| Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: interim analysis of a phase II trial P Muus, C Legendre, K Douglas, M Hourmant, Y Delmas, B Herthelius, ... J Am Soc Nephrol 21 (suppl), 402A, 2010 | 42 | 2010 |
